Breaking News, Collaborations & Alliances

SK pharmteco, AaviGen Enter Strategic Gene Therapy Mfg. Pact

SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead gene therapy product AVG-101 for the treatment of heart failure.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SK pharmteco, a global CDMO for small molecules and advanced therapies, and AaviGen GmbH, a preclinical stage biotechnology company focused curative gene therapies for cardiovascular and cardiopulmonary diseases, entered a multi-year manufacturing agreement wherein SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead gene therapy product AVG-101 for the treatment of heart failure.    AaviGen’s heart-specific adeno-associated viral vector technology enables the developmen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters